Female gender as a susceptibility factor for drug-induced liver injury
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Adverse drug reactions (ADRs) can involve all tissues and organs, but liver injuries are considered among the most serious. A number of prospective, multicenter studies have confirmed a higher risk of ADRs in general among female subjects compared to a male cohort. Although drug-induced liver injury (DILI) is infrequently encountered, the preponderance of evidence suggests that women appear to be more susceptible than men to fulminate hepatic/acute liver failure especially in response to some anti-infective drugs and to autoimmune-like hepatitis following exposure to certain other therapeutic drugs. A number of hypotheses have been proposed to explain this sex difference in susceptibility to DILI. Collectively, these hypotheses suggest three basic sex-dependent mechanisms that include differences in various aspects of drug pharmacokinetics (PK) or pharmacodynamics following the administration of certain drugs; specific hormonal effects or interactions with immunomodulating agents or signaling molecules; and differences in the adverse response of the immune system to some drugs, reactive drug metabolites, or drug-protein adducts. At the preclinical drug safety stage, there is a need for more research on hormonal effects on drug PK and for additional research on gender differences in aberrant immune responses that may lead to idiosyncratic DILI in some female patients. Because the detection of rare but serious hepatic ADRs requires the exposure of very large patient populations, pharmacovigilance networks will continue to play a key role in the postmarketing surveillance for their detection and reporting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227 · cited 1×
“In yet another study of 308 consecutive patients with ALF admitted to 17 tertiary care centers in the US, 73% were women.(87) APAP overdose (39% of cases) and idiosyncratic drug reactions (13% of cases) were the most frequent apparent causes of ALF.”
BackgroundSex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163 · cited 1×
“Because gastric alcohol dehydrogenase is lower in females than males, women tend to have a lower alcohol toxic threshold than men.(66) Moreover, it has been established clinically that women develop ALI more rapidly and to greater extent than men while consuming fewer grams of alcohol.”
BackgroundN-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen.
Dahlin, D. C., Miwa, G. T., Lu, A. Y., & Nelson, S. D. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1327 · Cited by 1,078
Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes
Waxman, D. J., & Holloway, M. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056705 · Cited by 815
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Andrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309 · cited 1×
“Long-term follow up studies in a hepatotoxicity registry has indicated that cholestatic/mixed liver damage is more likely to become chronic while the severity is greater with the hepatocellular pattern.(92) An analysis of a computerized diagnoses database in an out-patient hepatology clinic in a Swedish University Hos…”
BackgroundGender-related differences in pharmacokinetics and their clinical significance
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00246.x · Cited by 281
Isoherranen, N., & Thummel, K. E. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050245 · Cited by 239 · cited 2×
“For example, recent studies have demonstrated that pregnancy, depending upon the stage, alters the activity of CYP2D6, CYP3A4 (increased), and CYP1A2 (decreased), and increases the activity of the renal transporters organic cation transporter and P-gp.33 Studies in rat and mouse models have demonstrated that growth ho…”
BackgroundIdiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
James, L. P., Letzig, L., Simpson, P. M., Capparelli, E., Roberts, D. W., Hinson, J. A., Davern, T. J., & Lee, W. M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026195 · Cited by 175 · cited 1×
“A single 10–15 g APAP dose, or occasionally less, can produce clinical evidence of liver injury while fatal fulminant disease is usually, although not always, associated with ingestion of 25 g.(78) Overdoses of APAP result in the generation of APAP-protein adducts which have been shown to provide an excellent correlat…”
BackgroundSex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver
Yang, L., & Li, Y. (2012) · Journal of Drug Metabolism & Toxicology · doi:10.4172/2157-7609.1000119 · Cited by 135
Drug-induced liver injury: a clinical update
Ghabril, M., Chalasani, N., & Björnsson, E. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283383c7c · Cited by 123 · cited 1×
“In the United States, the most common drugs leading to DILI are antibiotics, central nervous system agents, herbal/dietary supplements, and immunomodulatory agents.(52) The associations for human liver and skin ADR are known to involve human leukocyte antigen (HLA) genes for drugs such as abacavir and carbamazepine.”
Background
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
“Sex Women are reported to have a higher risk of ADRs in general.(73) Differences in male and female incidence rates have also been”
BackgroundSex differences in pharmacokinetics predict adverse drug reactions in women
Zucker, I., & Prendergast, B. J. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00308-5 · Cited by 777
Katarey, D., & Verma, S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s104 · Cited by 331
Devarbhavi, H., Joseph, T., Sunil Kumar, N., Rathi, C., Thomas, V., Prasad Singh, S., Sawant, P., Goel, A., Eapen, C. E., Rai, P., et al. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.11.002 · Cited by 87
Shi, A., Nguyen, H., Kuo, C. B., & Beringer, P. M. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.01.001 · Cited by 36
Metadata
- Authors
- Amacher, D. E.
- Venue
- Human & Experimental Toxicology
- Publisher
- SAGE Publications
- Published
- 2013-12-03
- Volume
- 33
- Issue
- 9
- Pages
- 928-939
- ISSN
- 0960-3271 (ISSN-L)
- 1477-0903
- OpenAlex
- W2117819389
- Cited by
- 111
- References
- 14
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.